Treatment References

  1. Global initiative for chronic Obstructive Lung Disease (GOLD 2017). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://goldcopd.org/.
  2. Kuyucu T, Güçlü SZ, Saylan B et al. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks Dergisi 2011;59:328–339.
  3. Ries AL, Bauldoff GS, Carlin BW et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007;131: 4S42S.
  4. Nici L, Donner C, Wouters E et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390–1413.
  5. Berry MJ, Rejeski WJ, Adair NE et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999;160:1248–1253.
  6. Taskin D, Fabbri LM. Respiratory Research. Long-acting Beta-agonists in the Management of Chronic Obstructive Pulmonary Disease: Current and Future Agents. Respir Res 2010;11:149.
  7. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004;1:345–351.
  8. van Noord JA. Tiotropium bromide. A viewpoint by JA van Noord. Drugs 2002;62:1204–5.
  9. Rabe KF. Anticholinergic drugs for the treatment of COPD are safe... are they? Chest 2010;137:1–3.
  10. Atrovent® HFA (ipratropium bromide HFA). Prescribing information. Updated August 2012.
    Available at: http://www.drugs.com/pro/atrovent-hfa.html.
  11. Spiriva 18 microgram inhalation powder, hard capsule. Summary of Product Characteristics. Updated January 2015. Accessed 13 October 2016. https://www.medicines.org.uk/emc/medicine/10039.
  12. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47–55.
  13. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19: 217–224.
  14. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093–1103.
  15. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–224.
  16. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209–216.
  17. Donohue J van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47–55.
  18. Keam SJ and Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004;3:247–268.
  19. Kesten S, Celli B, Decramer M et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J COPD 2009;4:397–409.
  20. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54.
  21. Wise RA, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491–501.
  22. Seebri Breezhaler Inhalation Powder, Hard Capsules 44mcg. Summary of Product Characteristics. Updated 30 July 2015. Accessed 13 October 2016. http://www.medicines.org.uk/emc/medicine/27138.
  23. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 vs placebo and tiotropium in patients with COPD: The GLOW2 study. Eur Respir J 2012;40:1106–1114.
  24. D'Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011:12:156.
  25. Beeh KM, Singh D, Di Scala L et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503–513.
  26. Eklira Genuair 322 micrograms inhalation powder. Summary of Product Characteristics. Updated 28 April 2015. Accessed 13 October 2016. http://www.medicines.org.uk/emc/medicine/27001.
  27. Beier J, Kirsten A-M, Mróz R et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD 2013;10:511–522.
  28. Kerwin EM, D'Urzo AD, Gelb AF et al. ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9:90–101.
  29. Jones PW, Singh D, Bateman ED et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830–836.
  30. Wedzicha JA, Agusti A, Donaldson G, et al. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: a pooled analysis of five phase III, randomized, placebo-controlled studies. COPD 2016:1–9 [Epub ahead of print].
  31. D'Urzo A, Kerwin E, Rennard S et al. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD 2013:10:500–510.
  32. Incruse 55 micrograms inhalation powder, pre-dispensed. Summary of Product Characteristics. Updated 12 November 2015. Accessed 13 October 2016. http://www.medicines.org.uk/emc/medicine/29394.
  33. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg CJ, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538–1546.
  34. Celli BR, Crater G, Kilbride S et al. Once daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;145:981–991.
  35. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998;158: S146–S153.
  36. Serevent Evohaler. Summary of Product Characteristics. Updated 30 July 2014. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/17201.
  37. Boyd G, Morice AH, Pounsford JC et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815–821.
  38. Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273–279.
  39. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010;11:149.
  40. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.
  41. Formoterol Easyhaler 12 micrograms per dose inhalation powder. Summary of Product Characteristics. Updated 28 April 2015. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/19503.
  42. Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058–1069.
  43. Onbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsules. Summary of Product Characteristics. Updated 13 October 2014. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/23260.
  44. Donohue JF, Fogarty C, Lötvall J et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155–162.
  45. O'Donnell DE, Casaburi R, Vincken W et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030–1036.
  46. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011;140:68–75.
  47. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38:797–803.
  48. Brovana PI. Available at: https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088566.pdf.
  49. Baumgartner RA, Hanania NA, Calhoun WJ et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007;29:261–278.
  50. Hanania NA, Donohue JF, Nelson H et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD 2010;7:17–31.
  51. James F, Donohue, MD; Nicola A et al. One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD. Chest journal 2014. Available at: http://publications.chestnet.org/collection.aspx?
    categoryID=6270&page=1&isJournal=1
    .
  52. Striverdi Respimat 2.5 microgram, solution for inhalation. Summary of Product Characteristics. Updated March 2016. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/28992.
  53. Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 2015;75:665–673.
  54. Fukuchi Y Nagai A, Seyama K et al. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol. Treat Respir Med 2005;4:447–455.
  55. Ichikawa T, et al. Long-term safety, efficacy, and patient acceptability of the tulobuterol patch. Research and reports in transdermal drug delivery. 2013.
  56. Barnes PJ. Theophylline. Pharmaceuticals (Basel) 2010;3:725–747.
  57. Cazzola M, Matera MG, O'Donnell KM. Association of β2-adrenergic agonists and tiotropium: is the combination justified? Archivos de Bronconeumol. 2005;41:24–31.
  58. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009;6:404–415.
  59. Cazzola M, Matera MG. The effective treatment of COPD: Anticholinergics and what else? Drug Discov Today Ther Strateg 2006;3: 277–286.
  60. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest 1997;112:1514–1521.
  61. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156–160.
  62. Boehringer Ingelheim. COMBIVENT RESPIMAT prescribing information. Updated June 2016. Last accessed 14 October 2016. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Combivent%20Respimat/CMVTRSPT.pdf.
  63. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101–108.
  64. Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol 2015;79:695–708.
  65. Bateman ED, Mahler DA, Vogelmeier CF, et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014;8:357–379.
  66. Rabe KF, Timmer W, Sagkriotis A et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134:255–262.
  67. Vogelmeier CF, Bateman ED, Pallante J et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51–60.
  68. Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199–209.
  69. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374:2222–2234.
  70. Ultibro Breezhaler. Summary of Product Characteristics. Updated 9 October 2015. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/29533.
  71. Utibron Neohaler. Prescribing Information. Accessed 01 June 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000LBL.pdf.
  72. Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed. Summary of Product Characteristics. Updated March 2016. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/28949.
  73. Anoro Ellipta. Prescribing Information. Revised February 2016. Accessed 14 October 2016. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing
    _Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG.PDF
    .
  74. Spiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution. Summary of Product Characteristics. Updated March 2016. Accessed 14 October 2016. https://www.medicines.org.uk/emc/medicine/30495.
  75. BEVESPI AEROSPHERE. Prescribing Information. Revised April2016. Accessed 14 October 2016. http://www.azpicentral.com/bevespi/bevespi_pi.pdf.
  76. Stiolto Respimat. Prescribing Information. Revised June 2016. Accessed 14 October 2016. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Stiolto%20Respimat/stiolto.pdf.
  77. Duaklir Genuair 340 micrograms /12 micrograms inhalation powder. Summary of Product Characteristics. Updated 22 August 2016. Accessed 14 October 2016. http://www.medicines.org.uk/emc/medicine/29652.
  78. Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484–1494.
  79. Mahler DA, Decramer M, D'Urzo A et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J 2013; 43:1599–609.
  80. Dahl R, Chapman KR, Rudolf M et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558–1567.
  81. Rodrigo GJ, Neffen H. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Chest 2015;148:397–407.
  82. Donohue J, Niewoehner D, Brooks J et al. Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD. Eur Respir J 2013;42(Suppl. 57):P760.
  83. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014;14:178.
  84. D'Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014;15:123.
  85. Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J 2016;48:1030–1039.
  86. Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res 2015;16:92.
  87. Donohue JF, Soong W, Wu X, et al. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD. Respir Med 2016;116:41–48.
  88. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45:969–79.
  89. Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chron Obstruct Pulmon Dis 2016;11:193–205.
  90. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015;109:1312–1319.
  91. Martinez FJ, Rabe KF, Rodriguez-Roisin R, et al. Pooled analyses from PINNACLE-1 and -2: the novel LAMA/LABA co-suspension technology glycopyrrolate/ formoterol fixed-dose combination delivered by MDI shows improvement versus monocomponents in patients with COPD. Am J Respir Crit Care Med 2016;193:Abstract A6782. Accessed 14 October 2016. http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A6782.
  92. Adcock IM, Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2014;55:256–266.
  93. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002;15: 35–50.
  94. Lahu G, Nassr N, Hunnemeyer A. Pharmacokinetic evaluation of roflumilast. Expert Opin Drug Metab Toxicol 2011;7:1577–91.
  95. Calverley PM, Rabe KF, Goehring UM et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685–694.
  96. Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695–703.
  97. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385:857–866.
  98. Crim C, Calverley PM, Anderson JA et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34: 641–647.
  99. Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013;8:295–304.
  100. Vestbo J, Vogelmeier C, Small M et al. Understanding the GOLD 2011 Strategy as applied to a real-world COPDpopulation. Respir Med 2014;108:729–736.
  101. Nannini LJ, Cates CJ, Lasserson TJ et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; CD006829.
  102. Kim JH, Park JS, Kim KH et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013;143:1018–1024.
  103. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013;22:92–100.
  104. Yawn BP, Suissa S, Rossi A. Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med 2016;26:16068.
  105. Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014;15:77.
  106. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285–1294.
  107. Montuschi P, Malerba M, Macis G, et al. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today 2016 [Epub ahead of print].
  108. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545–555.
  109. Welte T, Miravitlles M, Hernandez P et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741–750.
  110. Singh D, Brooks J, Hagan G et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592–598.
  111. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963–973.
  112. Breekveldt-Postma NS, Koerselman J, Erkens JA et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007;101:1398–1405.
  113. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831–838.
  114. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007;101:1895–1902.
  115. Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435–441.